Study of an experimental drug for advanced bladder and other cancers
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called LY4052031 for people with advanced or metastatic cancers, especially bladder cancer. The drug aims to slow or stop tumor growth. Doctors will check if it is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic bladder cancer, or another type such as triple-negative breast, lung, esophageal, pancreatic, ovarian, cervical, head and neck, or prostate cancer.
- You have already received the standard treatments for your cancer, or no standard treatment is available. Some groups require at least one prior treatment, and one group requires no prior treatment.
- You have measurable disease (a tumor that can be measured on scans) for most groups, or non-measurable disease for one group.
- Your performance status is 0 or 1, meaning you are fully active or able to do light work.
- You have a tumor tissue sample available from a previous biopsy, or you are willing to have a new biopsy.
- You do not have uncontrolled brain metastases, high calcium levels, diabetes, eye problems, heart disease, or other serious health issues listed in the exclusion criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
This study tests adding new treatments to a standard therapy (enfortumab vedotin and pembrolizumab) for people with advanced bladder cancer that hasn't been treated before. It aims to find out if these combinations are safe and work better.
This trial tests a combination of three drugs (N-803, pembrolizumab, and enfortumab vedotin) for advanced bladder cancer that has not been treated with systemic therapy. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
This trial adds an investigational drug, GB-4362, to a standard combination of two medicines (enfortumab vedotin and pembrolizumab) for advanced bladder cancer. The study wants to see if adding this drug is safe and helps treat the cancer better.
Hear when a new Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.